Posts By :

Dr.Boomi

Molecular therapy for safeguarding your heart against cardiac dysfunction: Enoxacin-based therapy for cardiomyocyte proliferation and heart regeneration: Enoxacin, commonly used in the treatment of UTI and gonorrhea, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/June/2021, 7.17 pm

Molecular therapy for safeguarding your heart against cardiac dysfunction: Enoxacin-based therapy for cardiomyocyte proliferation and heart regeneration: Enoxacin, commonly used in the treatment of UTI and gonorrhea, decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/June/2021, 7.17 pm 960 720

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Molecular therapy for safeguarding your heart against cardiac dysfunction: Bergenin-based therapy for cardiomyocyte proliferation and heart regeneration: Bergenin decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/June/2021, 7.01 pm

Molecular therapy for safeguarding your heart against cardiac dysfunction: Bergenin-based therapy for cardiomyocyte proliferation and heart regeneration: Bergenin decreases tumor suppressor Mir-128 and cyclin-dependent kinase inhibitor p27 expression, increases SUZ12 expression, increases Cyclin E and CDK2 expression, promotes proliferation/re-entry of postnatal/adult cardiomyocytes, attenuates fibrosis, ameliorates cardiac dysfunction, and promotes heart repair in response to myocardial infarction, via up-regulation of its target gene, 26/June/2021, 7.01 pm 960 720

Introduction: What they say: A recent study from Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA; Key Laboratory of Molecular Target and…

read more

Little RNA can save you from cardiac hypertrophy and fibrosis: Intracardiac injection of LncRNA NEAT1 protects against cardiac hypertrophy and fibrosis: Intracardiac  injection of LncRNA NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 31/March/2021, 12.11 am

Little RNA can save you from cardiac hypertrophy and fibrosis: Intracardiac injection of LncRNA NEAT1 protects against cardiac hypertrophy and fibrosis: Intracardiac  injection of LncRNA NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 31/March/2021, 12.11 am 960 720

Introduction: What they say:   A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…

read more

LncRNA-based regenerative cardiovascular therapy: LncRNA FLVCR1-AS1 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 29/March/2021, 11.55 pm

LncRNA-based regenerative cardiovascular therapy: LncRNA FLVCR1-AS1 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 29/March/2021, 11.55 pm 960 720

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of the journal Nature,  by Profs. Stefanie Dimmeler…

read more

LncRNA-based regenerative cardiovascular therapy: LncRNA METRNL inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 29/March/2021, 11.51 pm

LncRNA-based regenerative cardiovascular therapy: LncRNA METRNL inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 29/March/2021, 11.51 pm 960 720

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of the journal Nature,  by Profs. Stefanie Dimmeler…

read more

LncRNA-based regenerative cardiovascular therapy: LncRNA BCAR4 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 17/March/2021, 5.40 pm

LncRNA-based regenerative cardiovascular therapy: LncRNA BCAR4 inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 17/March/2021, 5.40 pm 960 720

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of the journal Nature,  by Profs. Stefanie Dimmeler…

read more